Teva Pharmaceutical/$TEVA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Teva Pharmaceutical
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
- Ticker
- $TEVA
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 32,008
- Headquarters
- Tel Aviv-Yafo, Israel
- Website
- www.tevapharm.com
TEVA Metrics
BasicAdvanced
$48B
68.66
$0.60
-
-
Price and volume
Market cap
$48B
52-week high
$42.02
52-week low
$38.11
Financial strength
Current ratio
0.879
Quick ratio
0.457
Long term debt to equity
1.598
Total debt to equity
2.178
Interest coverage (TTM)
3.81%
Profitability
EBITDA (TTM)
4,268
Gross margin (TTM)
52.46%
Net profit margin (TTM)
4.08%
Operating margin (TTM)
18.94%
Effective tax rate (TTM)
1.67%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
5.13%
Return on equity (TTM)
9.69%
Valuation
Price to earnings (TTM)
68.657
Price to revenue (TTM)
2.753
Price to book
6.21
Price to tangible book (TTM)
-4.17
Price to free cash flow (TTM)
35.391
Free cash flow yield (TTM)
2.83%
Free cash flow per share (TTM)
1.167
Growth
Revenue change (TTM)
4.13%
Earnings per share change (TTM)
-527.36%
3-year revenue growth (CAGR)
4.86%
10-year revenue growth (CAGR)
-1.21%
3-year earnings per share growth (CAGR)
-34.17%
10-year earnings per share growth (CAGR)
-8.71%
What the Analysts think about TEVA
Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.
Analyst projections of the future price of Teva Pharmaceutical stock.
Bulls say / Bears say
AUSTEDO, AJOVY and UZEDY grew 43% year on year in Q2 to more than $1 billion, and Teva raised its combined 2026 sales outlook to about $3.7 billion. That gives the shift towards higher-growth branded medicines measurable momentum. (Teva Pharmaceutical Industries)
Teva says it has reached investment-grade ratings from all three major agencies ahead of schedule and expects recent refinancing to cut financing costs by about $400 million next year. Lower interest costs could leave more cash available for growth investment and debt reduction. (American Banking News, Teva Pharmaceutical Industries)
Teva generated $622 million of free cash flow in Q2, up 31% year on year, and forecasts $2.0-$2.4 billion for 2026. That cash generation gives the company room to fund its strategy while continuing to address its debt. (The Motley Fool, Teva Pharmaceutical Industries)
The branded growth has not yet offset pressure in generics: Q2 revenue fell 1% year on year as generics revenue dropped 15%, including a 31% decline in US generics, mainly from tougher competition for generic Revlimid. Further erosion could keep overall sales under pressure. (Fierce Pharma, Teva Pharmaceutical Industries)
A US appeals court allowed CMS to treat AUSTEDO and AUSTEDO XR as one drug for Medicare price negotiations, rejecting Teva’s challenge on that point. The outcome leaves a key growth brand exposed to the programme’s pricing rules. (Midpage)
The Emalex acquisition is weighing on near-term reported profitability: Teva’s 2026 outlook includes about $770 million of related expenses, or roughly $0.66 per share of adjusted EPS impact. This leaves less earnings contribution from the underlying business in the near term. (Teva Pharmaceutical Industries)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2026.
TEVA Financial Performance
Revenues and expenses
TEVA Earnings Performance
Company profitability
Upcoming events
No upcoming events
TEVA News
AllArticlesVideos
Funds containing TEVA
AllUSDEURGBP
Fund name | Fund size | $TEVA weighting |
|---|---|---|
iShares USD Short Duration High Yield Corporate Bond£SDHG | $959M | 2.50% |
SPDR MSCI World Health Care£HEAW | $708M | 0.56% |
SPDR MSCI World Health Care$WHEA | $708M | 0.56% |
Xtrackers MSCI World Health Care$XDWH | $4.1B | 0.56% |
Xtrackers MSCI World Health Care£XWHS | $4.1B | 0.56% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.